Table 3.
Comparison of oral glucose tolerance-related indexes among all groups
| Group | HOMA-IR | LnHOMA-β | LnMBCI | LnIp/I0 | AUCins-OGTT | AUCins-OGTT/AUCglu-OGTT |
|---|---|---|---|---|---|---|
| Hyperthyroidism groups | ||||||
| TNGT | 1.47 ± 0.58 | 5.41 ± 1.08†,‡,§,||,¶ | 1.70 ± 0.43‡,¶ | 2.68 ± 0.40¶ | 139.82 ± 83.75†,|| | 7.17 ± 3.83‡,¶ |
| TIGR | 1.56 ± 0.56 | 4.88 ± 1.11*,¶ | 1.20 ± 0.78‡,§ | 2.65 ± 0.64¶ | 214.02 ± 105.07*,‡,¶ | 8.47 ± 3.85†,‡,¶ |
| TDM | 1.67 ± 0.72 | 4.59 ± 1.06*,¶ | 0.59 ± 0.21*,†,§,|| | 2.32 ± 0.51 | 137.61 ± 57.18†,|| | 4.67 ± 2.06*,§,|| |
| Control groups | ||||||
| NGT | 1.41 ± 0.52 | 4.79 ± 0.72*,¶ | 1.99 ± 0.90†,‡,||,¶ | 2.41 ± 0.52¶ | 178.37 ± 77.80¶ | 8.68 ± 3.70‡,¶ |
| IGR | 1.50 ± 0.47 | 4.71 ± 0.92*,¶ | 1.31 ± 0.79‡,§,¶ | 2.68 ± 0.67¶ | 199.66 ± 107.14*,‡,¶ | 8.38 ± 4.23‡,¶ |
| T2DM | 1.57 ± 0.63 | 3.75 ± 0.81*,†,‡,§,|| | 0.73 ± 0.39*,§,|| | 2.11 ± 0.57*,†,§,|| | 102.88 ± 43.66†,§,|| | 2.86 ± 1.92*,†,§,|| |
| F | 1.472 | 9.249 | 8.231 | 4.729 | 5.978 | 11.260 |
| P | 0.203 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
Data are presented as mean ± standard deviation. HOMA-β, MBCI, and Ip/I0 are presented as mean ± standard deviation, after conversion into normally distributed Ln values. *P<0.05 by one-way ANOVA (vs. TNGT); †P<0.05 by one-way ANOVA (vs. TIGR); ‡P<0.05 by one-way ANOVA (vs. TDM); §P<0.05 by one-way ANOVA (vs. NGT); ||P<0.05 by one-way ANOVA (vs. IGR); ¶P<0.05 by one-way ANOVA (vs. T2DM). Ln: Logarithm; HOMA-IR: Homeostatic assessment model of insulin resistance; HOMA-β: Homeostatic assessment model of β-cell function; MBCI: Modified β-cell function index; AUC: Area under the curve; TNGT: Hyperthyroidism with normal glucose tolerance; TIGR: Hyperthyroidism with impaired glucose regulation; TDM: Hyperthyroidism with diabetes mellitus; NGT: Normal glucose tolerance control group; IGR: Impaired glucose regulation control group; T2DM: Type 2 diabetes mellitus control group; ANOVA: Analysis of variance; IP/I0: Peak insulin/fasting insulin.